I spent 15 years building brands. I know how to position a product, write a claim, design packaging that communicates luxury, and create the emotional narrative that drives purchase decisions. I was good at it. And that is exactly why I do not trust the skincare industry's version of quality. I know what goes into making a product feel worth buying — and it has very little to do with how well it works.
The transition from strategist to formulator changed my evaluation criteria. As a strategist, I evaluated products by brand story, packaging quality, and sensory experience. As a formulator, I evaluate by ingredient concentration, delivery system, stability testing, and independent research. The two rankings rarely align. Some of the most expensive products have the weakest formulations. Some of the best formulations have the least compelling story.
My neuroscience training at Copenhagen Business School gave me a framework for understanding why people buy skincare the way they do. The dopamine hit of purchasing a new product, the satisfying texture, the beautiful bottle — these are all rewards the brain values more highly than the delayed, invisible benefits of consistent ingredient delivery. The brain chooses the immediate sensory reward over the long-term biological outcome, every time.
I calculated the marketing-to-R&D spend ratio across the industry. For most major brands, marketing budget is 3-5× the R&D budget. The product you buy costs three to five times more to sell to you than it cost to develop. The premium in the price is not for better ingredients — it is for the story that makes you believe the ingredients are better. I participated in this system for a decade.
NeoLabCare is the response to that complicity. The budget allocation is inverted: the majority of resources go to ingredient quality, formulation engineering, and packaging that preserves potency. The packaging is intentionally understated. The claims are intentionally clinical. The product is designed to perform, not to persuade. If the industry's standard approach is the benchmark, NeoLabCare is the inversion of nearly every assumption.